Waist Size May Predict Heart Failure Risk Better Than BMI

Central obesity and its inflammatory milieu in heart failure risk: an interpretive briefing

The Jackson Heart Study is described as a single-site, African-American–only cohort.

• The source summarizes a single-session presentation from the American Heart Association’s EPI|Lifestyle Scientific Sessions 2026, with findings not yet published in a peer-reviewed journal.
• The researchers used data from the Jackson Heart Study, focusing on adults who did not have heart failure at baseline.
• Follow-up duration had a median length of just under seven years.
• The analysis examined anthropometric measures and biomarker data: weight, body mass index (BMI), waist circumference, waist-to-height ratio (WHtR), and inflammation as indexed by high-sensitivity C-reactive protein (hs-CRP).

• Central obesity indicators—waist circumference and WHtR—emerged as predictors of heart failure (HF) risk over time.
• BMI did not predict HF risk in the study’s analyses.
• Inflammation, operationalized by hs-CRP levels, was associated with lower HF-free survival, indicating a greater risk of developing HF among those with higher inflammatory burden.
• A mediation analysis evaluated whether hs-CRP explained some portion of the relationship between central obesity measures and HF risk.

• About 25.4% of the waist circumference effect on HF risk was mediated by hs-CRP.
• About 28.5% of the WHtR effect on HF risk was mediated by hs-CRP.

• The full study details, including a formal HF definition, comprehensive biomarker panels, imaging data, or explicit risk adjustments, are not available in the source because the study has not undergone peer review or full publication.
• The cohort’s demographic scope (African-American adults from a single site) limits generalizability to broader populations; extrapolation should be cautious.
• Several acknowledged limitations reported by the expert commentators include absence of a formal HF diagnostic Criteria within the presented materials, potential residual confounding, and the possibility that hs-CRP acts as a marker rather than a direct causal mediator of HF risk.
• Expert commentary emphasized that statistical mediation demonstrates an association pathway rather than definitive causal biology; other inflammatory mediators (e.g., IL-6, TNF-α) or interacting metabolic factors could contribute to observed risks.

• The findings align with a broader body of evidence linking abdominal (visceral) adiposity with adverse cardiovascular risk profiles, beyond measures of total adiposity such as BMI.
• Inflammation, as captured by hs-CRP, appears to partially account for the link between abdominal fat distribution and HF risk, suggesting a mechanistic pathway whereby visceral fat contributes to systemic inflammatory processes that may influence heart failure development.
• The authors and external commentators conveyed that the distribution of body fat—particularly central fat stores—may have greater prognostic relevance for HF risk than BMI alone.

• The study supports a focus on central obesity as a potentially more informative risk marker for HF than BMI, at least within this cohort.
• Inflammatory status, measured by hs-CRP, may partially mediate the link between central obesity and HF risk, underscoring inflammation as a relevant factor in cardiovascular risk assessment.
• The practical implication suggested in the source is that evaluating central fat distribution (waist circumference and WHtR) could enhance cardiovascular risk stratification for HF, alongside consideration of systemic inflammatory markers.

Elevated hs-CRP correlates with reduced HF-free survival.

The single-site, restricted-population nature of the cohort introduces uncertainty about broader applicability.

Critical biological questions remain regarding whether hs-CRP is a causal mediator, a marker of other inflammatory processes, or a proxy for concurrent metabolic disturbances.

Clarification of causal pathways linking visceral fat, inflammation, and HF.

Exploration of whether interventions targeting central obesity and systemic inflammation can modify HF risk across populations.

• Core signal: Central obesity indicators—waist circumference and WHtR—predict HF development in this African-American cohort, whereas BMI does not show a predictive association.
• Moderation pathway: Mediation analysis indicates that systemic inflammation accounts for roughly a quarter to nearly one-third of the association between central adiposity measures and HF risk, indicating inflammation as a partial intermediary rather than sole driver.
• Certainties and gaps: The lack of peer-reviewed publication at this time precludes confirmation of risk estimates, definitions, and analytic methods.
• Future directions implied by the commentary: Validation of these results in more diverse populations and with comprehensive HF definitions and biomarker panels.

• Because the study has not been published in a peer-reviewed journal, and full methodological details are unavailable, the potential biases or confounding factors cannot be fully assessed.
• Generalizability is constrained by the single-site, African-American focus; results may differ in other ethnic groups or multi-site cohorts.
• The commentary notes that inflammation markers can be complex and that mediation analyses require cautious interpretation regarding causality.

In sum, the presented material highlights a potential hierarchy in cardiovascular risk assessment: central adiposity signals may outperform BMI in predicting HF risk within the studied cohort, with systemic inflammation contributing to part of that risk.

The findings prompt cautious consideration of central obesity and inflammatory status in HF risk appraisal while awaiting peer-reviewed publication and broader validation.

• Do these associations persist in non-African American populations, and across different age groups and comorbidity profiles?
• How do additional inflammatory markers or adiposity measures (e.g., imaging-derived visceral fat) influence HF risk?
• Could targeted reduction of central adiposity and systemic inflammation meaningfully reduce HF incidence, and what are the most effective strategies across varied populations?